| abstract |
Compositions and methods are provided for the diagnosis, prognosis, and treatment of AR-related diseases, such as prostate diseases such as prostate cancer, breast cancer, and many other diseases. In particular, a novel clinically relevant mutation at position 876 of the androgen receptor (AR) has been identified. Drug sensitivity can be predicted and a treatment regimen can be planned based on the presence or absence of this mutation. Polypeptides comprising mutant AR, antibodies thereto, and polynucleotides encoding them can be used to identify new treatments. Double mutations in the AR at positions 741 and 877 have also been shown to be useful for patient stratification. |